LATERA® absorbable nasal implant system
LATERA supports upper and lower lateral nasal cartilage, which may reduce nasal airway obstruction (NAO) symptoms and help increase nasal airflow.1
Features and benefits
- The forked tip helps securely anchor the implant in place6-8
- Implants are available in 20mm and 24mm lengths and are made of absorbable PLLA polymer6-8
- The atraumatic ball tip is designed to minimize tissue damage6-8
Related categories
How is the LATERA implant absorbed?
The LATERA implant is absorbed over a period of approximately 18 months.7 Post implantation, a fibrous capsule forms and the integrity of the implant is maintained through 12 months. Tissue encapsulation promotes acute implant stability and enables localized tissue response during the absorption process. Remodeling occurs once the implant is replaced with fibrous collagen construct to provide ongoing support.2
- Implantation: Implant integrity maintained while fibrous capsule forms.2
- Encapsulation: Tissue encapsulation promotes acute implant stability. Safety profile shows minimal inflammatory response and expected surrounding tissue reaction.2
- Remodeling: Capsule and fibrotic tissue remains as implant degrades and is absorbed. Collagen construct replaces implant at approximately 24 months.2
Watch how the LATERA implant works
The LATERA implant is inserted with a 16-gauge cannula delivery device and supports the upper and lower lateral cartilage by anchoring above the maxilla to provide cantilever support.
Product specifications
| Product | Ordering no. | Description |
| LATERA absorbable nasal implant system | LATSYS20 | 20 mm, 1 system |
| LATERA absorbable nasal implant system | LATSYS24 | 24 mm, 1 system |
1 system includes: 1 implant delivery device, 2 absorbable nasal implants
Patient results
Patients treated with the Latera absorbable nasal implant showed significant improvement in symptoms when measured with the nasal obstruction symptom evaluation (NOSE) score up to 24 months.4
While individual results may vary, patients treated with LATERA absorbable nasal implant experienced the following symptom improvements:4
- Reduced nasal congestion or stuffiness
- Less trouble breathing through the nose
- Improved nasal breathing during exercise or exertion
- Reduced nasal blockage or obstruction
- Less trouble sleeping
Will my patient’s appearance change?
Patients experienced a reduction in nasal obstruction symptoms of 58.2% at two years, as measured by the NOSE survey. Most patients achieved these results without cosmetic changes.1, 4, 6, 9, 10
Risks include minor and temporary symptoms such as:1-10
- Mild bruising and inflammation
- Awareness of the implant
- Mild pain or irritation
Other risks related to the LATERA implant included: discomfort, infection, reaction to material and surgical implant removal.7
86%
of patients* were satisfied with their breathing after the procedure6
of patients* were satisfied with their breathing after the procedure6
93%
of patients* were satisfied with their appearance after the procedure6
of patients* were satisfied with their appearance after the procedure6
* Individual patient results may vary and may include other procedures.
What patients have experienced with LATERA
Interested in learning more about Latera? Contact your rep and set up a trial.
Thank you for your interest! We will be in contact soon.
REFERENCES
- San Nicolo M,et. al. 2017. Absorbable Implant to Treat Nasal Valve Collapse. Facial Plast Surg, 32:233-240.
- Rippy MK, Baron S, Rosenthal M, Senior BA. Evaluation of absorbable PLA nasal implants in an ovine model. Laryngoscope Investig Otolaryngol. 2018; 3(3):156-161
- Chandra RK, Patadia MO, Raviv J. Diagnosis of nasal airway obstruction. Otolaryngol Clin North Am. 2009 ;42(2):207-25.
- San Nicoló M, Stelter K, Sadick H, Bas M, Berghaus A. A 2-Year Follow-up Study of an Absorbable Implant to Treat Nasal Valve Collapse. Facial Plast Surg 2018; 10.1055/s-0038-1672213.
- Stolovitzky, et. al. 2018. A Prospective Study for Treatment of Nasal Valve Collapse Due to Lateral Wall Insufficiency: Outcomes Using a Bioabsorbable Implant. Laryngoscope.
- Data on file TR-21076 Spirox NVC Experience. Survey results of 272 patients.
- LATERA Instructions for Use 4645-002
- Stryker Data on File DC-0000002742
- Bikhazi N, Ow, R, O’Malley E, Perkins N, Sidle D, Stolovitzky P. Long-term Follow-up from the Treatment and Crossover Arms of a Randomized Controlled Trial of an Absorbable Nasal Implant for Dyanamic Nasal Valve Collapse. Facial Plastic Surgery. Accepted November 16, 2021
- Sidle, D. M., Stolovitzky, P., O'Malley, E. M., Ow, R. A., Nachlas, N. E., & Silvers, S. (2021). Bioabsorbable Implant for Treatment of Nasal Valve Collapse with or without Concomitant Procedures. Facial Plast Surg, 37(5), 673-680
DISCLAIMER
This document is intended solely for the use of healthcare professionals. A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. We do not dispense medical advice and recommend that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate Stryker’s products. A surgeon must always refer to the package insert, product label and/or instructions for use, including the instructions for cleaning and sterilization (if applicable), before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your representative if you have questions about the availability of Stryker’s products in your area.
Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: LATERA and Stryker. All other trademarks are trademarks of their respective owners or holders.
The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker’s trademark or other intellectual property rights concerning that name or logo.
ENT-LATSYS-SYK-665351_REV-1